生物科技公司莫德纳(MRNA)周四股价大跌5.29%,报收于47.33美元。此前该股一度下跌逾6%,引发市场广泛关注其下跌原因。
在宏观面上,莫德纳公司虽然在上周发布了2024年第三季度财报,财报数据超出市场预期,收益和利润均显著增长。但公司同时预计,在2025年下半年之前,RSV呼吸道合胞病毒疫苗不太可能实现大规模销售。
此外,加拿大政府日前宣布,批准莫德纳公司的RSV疫苗供60岁及以上成年人使用。尽管这是一个利好消息,有望推动该款疫苗在加拿大市场的销售,但短期内可能难以完全抵消市场担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.